domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP
 
 The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-16*
+
+International generic competition beginning in 2026 will compress prices far faster than the 'inflationary through 2035' timeline assumes. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens to generics March 2026. China has 17+ Phase 3 generic candidates targeting $40-$50/month pricing. India patents expire March 2026. Even accounting for US regulatory delays (patents to 2031-2032), international price arbitrage and compounding pharmacy pressure will drive US prices below $100/month well before 2035. At $50-100/month, GLP-1s become unambiguously cost-effective under any payment model, fundamentally changing the cost trajectory from inflationary to cost-saving.
+
 ---
 
 Relevant Notes:

inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md

@@ -7,9 +7,13 @@ date: 2026-02-01
 domain: health
 secondary_domains: [internet-finance]
 format: article
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -50,3 +54,16 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong
 EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure
+
+
+## Key Facts
+- Semaglutide US patents extend to 2031-2032
+- Canada semaglutide patents expired January 4, 2026
+- Brazil generic semaglutide competition opens March 2026
+- China has 17+ generic semaglutide candidates in Phase 3 trials
+- India semaglutide patents expire March 2026
+- Oral Wegovy launched January 2026 at $149-$299/month
+- Medicare negotiated price: $245/month for oral Wegovy
+- Projected China/India generic pricing: $40-$50/month
+- Sandoz, Apotex, and Teva filed for Canadian generic semaglutide immediately after patent expiry
+- Biomm + Biocon (India) preparing generic semaglutide for Brazil market